Fairview Capital Partners

Inbox Health Corp. is a digital healthcare company that focuses on improving patient communication regarding medical billing in the United States. Established in 2014 and based in New Haven, Connecticut, the company offers a platform that automates the patient communication process through bi-directional correspondence and advanced technologies such as machine learning and artificial intelligence. This platform helps patients better understand their medical bills and provides various payment options. By analyzing data from its customer base, Inbox Health enables medical billers to customize the billing and communication experience for each patient, thereby enhancing collections and overall patient satisfaction. The company's mission is to reduce administrative inefficiencies in healthcare by streamlining the billing and payment processes for patients.

Inbox Health Corp. is a digital healthcare company that focuses on improving patient communication regarding medical billing in the United States. Established in 2014 and based in New Haven, Connecticut, the company offers a platform that automates the patient communication process through bi-directional correspondence and advanced technologies such as machine learning and artificial intelligence. This platform helps patients better understand their medical bills and provides various payment options. By analyzing data from its customer base, Inbox Health enables medical billers to customize the billing and communication experience for each patient, thereby enhancing collections and overall patient satisfaction. The company's mission is to reduce administrative inefficiencies in healthcare by streamlining the billing and payment processes for patients.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.